Pharmacodynamic Effects of Vorapaxar in Patients With and Without Diabetes Mellitus: Results of the OPTIMUS-5 Study.
JACC Basic Transl Sci
; 4(7): 763-775, 2019 Nov.
Article
em En
| MEDLINE
| ID: mdl-31998847
ADP, adenosine diphosphate; CAT, collagen-related peptide + adenosine diphosphate + thrombin receptor activating peptide; CI, confidence interval; COX, cyclooxygenase; DAPT, dual antiplatelet therapy; DM, diabetes mellitus; LTA, light transmittance aggregometry; MI, myocardial infarction; MPA, maximum platelet aggregation; PAD, peripheral arterial disease; PAR, protease-activated receptor; PD, pharmacodynamic; TRAP, thrombin receptor activating peptide; TXB2, thromboxane B2; VASP, vasodilator-stimulated phosphoprotein; dual antiplatelet therapy; o.d., once daily; pharmacodynamics; platelets; thrombin; vorapaxar
Texto completo:
1
Base de dados:
MEDLINE
Idioma:
En
Revista:
JACC Basic Transl Sci
Ano de publicação:
2019
Tipo de documento:
Article